BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TT-4 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TT-4\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04969315-2783@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:TT-4: Phase 1/2 readout est. (NCT04969315)
DESCRIPTION:TT-4\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TT-4 and
  TT-10 as Single Agents and in Combination in Subjects With Advanced Selec
 ted Solid Tumors and Pleural Mesothelioma\nEstimated primary completion: 1
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tt-4#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0496
 9315
URL:https://assetmemo.bio/drug/tt-4#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
